A 57-year-old man developed symptoms of a respiratory tract infection which was treated with erythromycin BP. He subsequently went into acute liver failure. Investigation of a very prolonged prothrombin time revealed a marked, selective factor X deficiency (1% of normal activity). He later recovered virtually normal liver function and completely normal factor X activity.
Introduction
Selective factor X deficiency is a very rare condition occurring as the hereditary Stuart Prower disease (Telfer, Denson and Wright, 1956) and as an acquired form in patients with paraproteinaemia (Lackner, 1973) and amyloidosis (Dam et al., 1975) . Recently, a case of acquired, transient factor X deficiency has been described following Mycoplasma pneumonia (Peuscher et al., 1979) . We report a case arising in a man who developed acute liver failure after a chest infection partially treated with erythromycin BP. Neither the cause of his factor X deficiency nor that of his acute liver failure was immediately obvious.
Case report
A 57-year-old man presented in May 1981 to his general practitioner with a 2-day history of cough and rigors, for which he was treated with erythromycin BP, 250 mg 4 times a day. Twenty-four hours later, he developed a rash and 6 days later he complained of epistaxis and pale stools. He was noted to be jaundiced and pyrexial, and was admitted to hospital. He was treated with a standard liver failure regimen and intravenous antibiotics. He improved rapidly over the next 5 days but the prothrombin time increased despite the administration of 11 units of fresh frozen plasma and 8 units of factor IX concentrate (which also contains large amounts of factors II and X). By 5 days after admission, the prothrombin time was over 5 min (control 22 s) with no spontaneous bleeding. No more plasma or factor IX concentrate was given and 9 days after admission the prothrombin time had fallen to 129 s (control 24) and the factor X activity had risen to 4%. At followup 1 month after admission, he was well, prothrombin time was 31 s (control 23) with a factor X activity of 136%, AST 48 (Lunzer et al., 1975) , but there have been 2 recent reports of cholestatic jaundice following erythromycin ethylsuccinate (Viteri, Greene and Dyck, 1979; Sullivan, Csuka and Blanchard, 1980 
